OBIO vs. CBLL, BVS, AVNS, IRMD, BFLY, SIBN, KIDS, TMCI, SMLR, and NNOX
Should you be buying Orchestra BioMed stock or one of its competitors? The main competitors of Orchestra BioMed include CeriBell (CBLL), Bioventus (BVS), Avanos Medical (AVNS), Iradimed (IRMD), Butterfly Network (BFLY), SI-BONE (SIBN), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), Semler Scientific (SMLR), and Nano-X Imaging (NNOX). These companies are all part of the "medical equipment" industry.
Orchestra BioMed vs.
CeriBell (NASDAQ:CBLL) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.
CeriBell currently has a consensus price target of $32.60, suggesting a potential upside of 39.32%. Orchestra BioMed has a consensus price target of $16.25, suggesting a potential upside of 209.52%. Given Orchestra BioMed's higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than CeriBell.
53.6% of Orchestra BioMed shares are owned by institutional investors. 6.7% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, CeriBell had 3 more articles in the media than Orchestra BioMed. MarketBeat recorded 3 mentions for CeriBell and 0 mentions for Orchestra BioMed. CeriBell's average media sentiment score of 0.67 beat Orchestra BioMed's score of 0.00 indicating that CeriBell is being referred to more favorably in the media.
CeriBell has a net margin of 0.00% compared to Orchestra BioMed's net margin of -2,179.33%. CeriBell's return on equity of 0.00% beat Orchestra BioMed's return on equity.
CeriBell has higher earnings, but lower revenue than Orchestra BioMed.
Orchestra BioMed received 4 more outperform votes than CeriBell when rated by MarketBeat users.
Summary
CeriBell beats Orchestra BioMed on 6 of the 11 factors compared between the two stocks.
Get Orchestra BioMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orchestra BioMed Competitors List
Related Companies and Tools
This page (NASDAQ:OBIO) was last updated on 1/22/2025 by MarketBeat.com Staff
Free OBIO Stock Alerts